Chemokines profile in patients with chronic heart failure treated with cardiac resynchronization therapy.

CONCLUSIONS: HF-REF patients present altered chemokines profile compared to the control group. The CRT-related alleviation of HF-REF causes only slight changes in the chemokines concentrations especially in the platelet-associated ones. The precise chemokines role in the HF-REF pathogenesis and their prognostic value remains to be established. PMID: 31923769 [PubMed - as supplied by publisher]
Source: Advances in Medical Sciences - Category: Biomedical Science Authors: Tags: Adv Med Sci Source Type: research

Related Links:

AbstractAimsDiabetes mellitus (DM) has a negative impact on prognosis in patients with heart failure (HF). The role impact of DM in HF patients with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices might differ and remains unclear. The aim of our study was to investigate the impact of DM on periprocedural complications and clinical outcome in HF patients undergoing ICD or CRT implantation.Methods and resultsWithin the German Device Registry, data from 50 German centres were collected between January 2007 and February 2014. A retrospective analysis ofn = 5329 patients undergoin...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
Cardiac resynchronization therapy (CRT) reduces the risk of mortality and heart failure events in select patients with left ventricular systolic dysfunction.1 –4 Prior studies have suggested underuse of CRT among eligible patients.5 Within a large regional health care system, we sought to identify and address potential underuse of CRT.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Research Letter Source Type: research
Publication date: Available online 21 February 2020Source: American Heart JournalAuthor(s): Marat Fudim, Frederik Dalgaard, Sana M. Al-Khatib, Daniel Friedman, Kathryn Lallinger, William T. Abraham, John G.F. Cleland, Anne B. Curtis, Michael R. Gold, Valentina Kutyifa, Cecilia Linde, Daniel E. Schaber, Anthony Tang, Fatima Ali-Ahmed, Sarah Goldstein, Brystana Kaufman, Robyn Fortman, J. Kelly Davis, Lurdes Y.T. Inoue, Gillian D. SandersAbstractBackgroundAlthough cardiac resynchronization therapy (CRT) is effective for some patients with heart failure and a reduced left ventricular ejection fraction (HFrEF), evidence gaps re...
Source: American Heart Journal - Category: Cardiology Source Type: research
CONCLUSIONS: Among HF patients with LVEF ≤ 35%, clinical factors including older age, CAD, and previous MI are associated with transmural LGE in the posterolateral wall, while CAD is associated with LGE. This data may have potential implications for planning ICD and CRT placement procedures. PMID: 32037500 [PubMed - as supplied by publisher]
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research
Publication date: February 2020Source: Canadian Journal of Cardiology, Volume 36, Issue 2Author(s): Ashlay A. Huitema, Karen Harkness, Shiraz Malik, Neville Suskin, Robert S. McKelvieAbstractGlobally, there are ∼ 26 million people living with heart failure (HF), 50% of them with reduced ejection fraction, costing countries billions of dollars each year. Improvements in treatment of cardiovascular diseases, including advanced HF, have allowed an unprecedented number of patients to survive into old age. Despite these advances, patients with HF deteriorate and often require advanced therapies. As the proportion of elderly...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
This study aimed to investigate eligibility, titration, and tolerability for Sac/Val in a real ‐world clinical setting.Methods and resultsThis retrospective cohort study consists of two parts. In Part 1 (eligibility study), all patients discharged from Sahlgrenska University Hospital due to HF were consecutively included during 1 year. Data from the patients' medical records were collected. Patients were adjudicated to be eligible based on European Society of Cardiology (ESC) criteria for angiotensin receptor neprilysin inhibitor (ARNI) with the exception of N ‐terminal (NT)‐proBNP levels. Patients who received
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
ConclusionsPatients with large decreases in PA have significantly higher risk of experiencing heart failure hospitalization or death. PA data from implantable devices may identify patients before clinical decompensation.Central Illustration
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
Abbott Laboratories continues to extend its list of milestones in the cardiovascular space. The Abbott Park, IL-based company has now won Breakthrough Device Designation from FDA for the in-development Fully Implantable Left Ventricular Assist System (FILVAS). FILVAS builds on the HeartMate 3 Left Ventricular Assist Device (LVAD). The technology was inherited by St. Jude Medical when it was acquired by Abbott. St. Jude inherited Heartmate 3 after it acquiredThoratec for $3.4 billion. Kevin Bourque, Divisional Vice President of Research &Development for Abbott’s Mechanical Circulatory Support portfol...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Regulatory and Compliance Source Type: news
Michel Mirowski and his colleagues gave the field of implantable cardioverter-defibrillators (ICDs) a pretty good start, but what's more impressive is how far the technology has advanced since that first human ICD implant in February 1980. In the past 40 years we've seen ICDs become dramatically smaller, longer lasting, more capable, more personalized, subcutaneous (non-transvenous), and even MRI-firendly. And that's not to mention the advanced data connectivity and monitoring capabilities that the latest technologies offer. So without further ado, let's take a look at the current ICD landscape and the companie...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
Conclusion Reducing the nonresponder rate continues to be an important goal for CRT. If an increase in reverse remodelling can be achieved by MPP, this study supports the conduct of larger trials investigating the role of MPP on clinical outcomes in selected patients treated, right now, only with traditional CRT. Trial registration, NCT02713308. Registered on 18 March 2016.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Study design Source Type: research
More News: Biomedical Science | Cardiac Resynchronization Therapy | Cardiology | Heart | Heart Failure | Study